抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 維甲酸誘導(dǎo)蛋白6抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。

產(chǎn)品訂購信息：
英文名稱  Anti-STRA6 

中文名稱   維甲酸誘導(dǎo)蛋白6抗體品牌 

別    名  Stimulated by retinoic acid gene 6 protein homolog; STRA6_HUMAN.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Horse, Rabbit 

產(chǎn)品類型   一抗  

研究領(lǐng)域     細(xì)胞生物 信號轉(zhuǎn)導(dǎo) 細(xì)胞類型標(biāo)志物

蛋白分子量  predicted molecular weight: 74kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from Human STRA6 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

維甲酸誘導(dǎo)蛋白6抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 STRA6 is a 667 amino acid, multi-pass cell membrane protein. Stra6 functions as a cell-surface receptor for the complex retinol-retinol binding protein (RBP/RBP4). Ultimately increasing cellular retinol uptake from the retinol-RBP complex, Stra6 removes retinol from RBP/RPB4 and transports it across the plasma membrane, where it is metabolized. Stra6 is broadly expressed, with 4 named isoforms that exist as a result of alternative splicing events. Mutations in the gene encoding Stra6 cause Matthew-Wood Syndrome, also known as Spear Syndrome. This syndrome is characterized by anophtalmia, mild facial dysmorphism and malformations of the heart, lung and diaphragm. The Stra6 gene maps to chromosome 15q24.1.

Function : Stra6 functions as a high-affinity cell-surface receptor for the complex retinol-retinol binding protein (RBP/RBP4). Stra6 is expressed in the extraembryonic endoderm and expression is also known to be induced by Wnt1. Defects in STRA6 are known to cause of syndromic microphthalmia type 9 (MCOPS9) also known as clinical anophthalmia with mild facial dysmorphism and variable malformations of the lung, heart, and diaphragm or anophthalmia/microphthalmia and pulmonary hypoplasia or Spear syndrome or Matthew-Wood syndrome or pulmonary agenesis, microphthalmia, and diaphragmatic defect.

Subcellular Location : Cell membrane; multi-pass membrane protein.

Tissue Specificity : Broad expression. In adult eye expressed in sclera, retina, retinal pigment epithelium, and trabecular meshwork but not in choroid and iris.

DISEASE : Defects in STRA6 are the cause of microphthalmia syndromic type 9 (MCOPS9) [MIM:601186]; also called Matthew-Wood syndrome or Spear syndrome. Microphthalmia is a clinically heterogeneous disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities. MCOPS9 is a rare clinical entity including as main characteristics anophthalmia or severe microphthalmia, and pulmonary hypoplasia or aplasia.

Note=Mutations in STRA6 may be a cause of isolated colobomatous microphthalmia, a disorder of the eye characterized by an abnormally small ocular globe.

抗體的鑒定：

1）維甲酸誘導(dǎo)蛋白6抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。

NKA(Neurokinin A) 神經(jīng)激肽A抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-APP/ABPP 淀粉樣肽前體蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Phospho-ATP1A1(Tyr10) 磷酸化ATP酶蛋白a1抗體 規(guī)格 0.1ml

山羊抗兔 IgG(H+L)/AP 0.1ml 美國Jackson公司分裝

V5 tag 英文名稱： V5 tag標(biāo)簽抗體 0.1ml

DKC1 英文名稱： 核仁蛋白NAP57抗體 0.2ml

Anti-APP/ABPP 淀粉樣肽前體蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-phospho-c-Jun (Ser243) /FITC 熒光素標(biāo)記磷酸化原癌基因c-Jun抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rabbit Anti-chicken IgM 兔抗雞IgM (親和層析純化)Multi-class antibodies規(guī)格： 1mg

胃泌素抑制肽抗體 Anti-GIP 0.2ml

Goat Anti-Bovine IgG/Cy3 Cy3標(biāo)記的羊抗IgG 0.1ml

FHL2 英文名稱： 相互作用蛋白FHL2抗體 0.1ml

Rhesus antibody Rh phospho-SIRT6(Ser338) 磷酸化沉默調(diào)節(jié)相關(guān)蛋白6抗體 規(guī)格 0.1ml

Rabbit Anti-chicken IgM 兔抗雞IgM (親和層析純化)Multi-class antibodies規(guī)格： 1mg

5HT1E Receptor 英文名稱： 5-羥色胺受體1E抗體 0.2ml

EMR1 英文名稱： 表皮生長因子樣激素受體1 0.2ml

腱糖蛋白-C抗體 anti-Tn-C 0.2ml

Anti-TNF- Alpha /HRP 辣根過氧化物酶標(biāo)記鼠抗人壞死因子-α單克隆抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Phospho-JunB (Thr102/Thr104) 磷酸化活化蛋白激酶B抗體 規(guī)格 0.2ml

PLGF (Placenta growth factor) 胎盤生長因子(多肽抗原)Multi-class antibodies規(guī)格： 0.5mg

786-O [786-0], 人腎透明腺癌細(xì)胞

NRK 大鼠腎細(xì)胞

GPA33 Others Human 人 GPA33 / Glycoprotein-A33 人細(xì)胞裂解液 (陽性對照)

非洲綠猴腎細(xì)胞;Vero E6

視網(wǎng)膜微內(nèi)皮細(xì)胞Many types of cells包裝：5 × 105次方(1ml)

人B細(xì)胞;RAMOS(RA.1) 大鼠*星狀細(xì)胞完全培養(yǎng)基 100mL

A-375 [A375], 人惡性黑素瘤細(xì)胞株

NINJ1 Others Rat 大鼠 Ninjurin-1 / NINJ1 人細(xì)胞裂解液 (陽性對照)

大鼠腦平滑肌細(xì)胞完全培養(yǎng)基 100mL

B95-8絨猴EBV轉(zhuǎn)化的白細(xì)胞 B95-8 EBV conversion of leukocyte marmoset RPMI-1640(GIBCO)+10%FBS

IFNA13 Protein Mouse 重組小鼠 IFNA13 / Ierferon alpha-13 蛋白 (Fc 標(biāo)簽)

MFC-GFP(小鼠前細(xì)胞(綠色熒光蛋白標(biāo)記)) 5×106cells/瓶×2 CTLL-2(T細(xì)胞)

維甲酸誘導(dǎo)蛋白6抗體品牌 786-O [786-0], 人腎透明腺癌細(xì)胞

NRK 大鼠腎細(xì)胞

GPA33 Others Human 人 GPA33 / Glycoprotein-A33 人細(xì)胞裂解液 (陽性對照)

非洲綠猴腎細(xì)胞;Vero E6

視網(wǎng)膜微內(nèi)皮細(xì)胞Many types of cells包裝：5 × 105次方(1ml)

人B細(xì)胞;RAMOS(RA.1) 大鼠*星狀細(xì)胞完全培養(yǎng)基 100mL